Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931

• M. Fevzi Ozkaynak,
• Andrew L. Gilman,
• Wendy B. London,
• Arlene Naranjo,
• Mitchell B. Diccianni,
• Sheena C. Tenney,
• Malcolm Smith,
• Karen S. Messer,
• Robert Seeger,
• C. Patrick Reynolds,
• L. Mary Smith,
• Barry L. Shulkin,
• Marguerite Parisi,
• John M. Maris,
• Julie R. Park,
• Paul M. Sondel,
• Alice L. Yu,
• Alice L. Yu

Affiliations

M. Fevzi Ozkaynak

New York Medical College, Valhalla, NY, United States

Andrew L. Gilman

Levine Children’s Hospital, Charlotte, NC, United States

Wendy B. London

Dana Farber Cancer Institute and Boston Children’s Hospital, Harvard Medical School, Boston, MA, United States

Arlene Naranjo

Children’s Oncology Group Statistics and Data Center, University of Florida, Gainesville, FL, United States

Mitchell B. Diccianni

Moores Cancer Center, University of California, San Diego, La Jolla, CA, United States

Sheena C. Tenney

Children’s Oncology Group Statistics and Data Center, University of Florida, Gainesville, FL, United States

Malcolm Smith

National Cancer Institute, Bethesda, MD, United States

Karen S. Messer

Moores Cancer Center, University of California, San Diego, La Jolla, CA, United States

Robert Seeger

Children’s Hospital Los Angeles, University Southern California, Los Angeles, Los Angeles, CA, United States

C. Patrick Reynolds

Texas Tech University Health Sciences Center, Lubbock, TX, United States

L. Mary Smith

United Therapeutics, Silver Spring, MD, United States

Barry L. Shulkin

0St. Jude’s Children’s Research Hospital, Memphis, TN, United States

Marguerite Parisi

1Seattle Children’s Hospital, University of Washington School of Medicine, Seattle, WA, United States

John M. Maris

2Children’s Hospital of Philadelphia, Philadelphia, PA, United States

Julie R. Park

1Seattle Children’s Hospital, University of Washington School of Medicine, Seattle, WA, United States

Paul M. Sondel

3University of Wisconsin Carbone Cancer Center, Madison, WI, United States

Alice L. Yu

Moores Cancer Center, University of California, San Diego, La Jolla, CA, United States

Alice L. Yu

4Institute of Stem Cell and Translational Cancer Research, Chang Gung Memorial Hospital, Taoyuan, Taiwan